Advertisement

Novel Inhaled Insulin Approved for Diabetes — Physician’s First Watch

Medical News |
June 30, 2014

Novel Inhaled Insulin Approved for Diabetes

By Kristin J. Kelley

Edited by Susan Sadoughi, MD, and Jaye Elizabeth Hefner, MD

The FDA on Friday approved a rapid-acting inhaled insulin powder (marketed as Afrezza) for treating types 1 and 2 diabetes. The drug — taken at mealtime — must be used in conjunction with long-acting insulin in those with type 1 diabetes.

In clinical trials, Afrezza was shown to be noninferior to standard mealtime injectable insulin for reducing hemoglobin A1c levels.

Patients with chronic lung disease (e.g., asthma, COPD) shouldn't use Afrezza due to an increased risk for bronchospasm; the drug's label carries a boxed warning to advise of this risk. It is also not recommended for smokers or for treating diabetic ketoacidosis. The most common side effects include cough, hypoglycemia, and throat pain.

The FDA previously rejected Afrezza twice, the New York Times reports, but an advisory panel finally voted to approve it this past April. Postmarketing studies will examine whether the inhaled insulin impairs lung function or increases the risk for lung cancer, and whether it's safe for children.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement